Sugi Predict

Sugi Predict / Compounds / SCHEMBL20116346

SCHEMBL20116346

SCHEMBL20116346

CCOc1ccc(-c2noc(C3CCN(C(=O)N4CCCCC4)CC3)n2)cc1OC

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 3/20 0.56
▸ KMT2A Q03164 3/20 0.56
▸ L3MBTL1 Q9Y468 2/20 0.56
▸ TSHR P16473 2/20 0.56
▸ HTT P42858 2/20 0.56
▸ CYP3A4 P08684 1/20 0.56
▸ CYP2C9 P11712 1/20 0.56
▸ CYP2C19 P33261 1/20 0.56
▸ USP2 O75604 1/20 0.55
▸ LMNA P02545 1/20 0.55
▸ SMO Q99835 1/20 0.53
▸ GRM5 P41594 2/20 0.52
▸ HPGD P15428 2/20 0.50
▸ SMN1; SMN2 Q16637 2/20 0.50
▸ NPC1 O15118 1/20 0.49
▸ RAB9A P51151 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20116343 0.92 TSHR (0.65) MEN1KMT2AL3MBTL1TSHRHTT
SCHEMBL22357775 0.90 SMO (0.55) MEN1KMT2AL3MBTL1TSHRHTT
SCHEMBL21609973 0.90 SMO (0.55) MEN1KMT2AL3MBTL1TSHRHTT
SCHEMBL20116374 0.85 SMO (0.51) MEN1KMT2AL3MBTL1TSHRHTT
SCHEMBL20116188 0.84 SMN1; SMN2 (0.58) MEN1KMT2AL3MBTL1TSHRHTT
SCHEMBL22357969 0.83 HTT (0.55) MEN1KMT2AL3MBTL1TSHRHTT
SCHEMBL22357786 0.83 HTT (0.50) MEN1KMT2AL3MBTL1TSHRHTT
SCHEMBL20116646 0.82 HTT (0.59) MEN1KMT2AL3MBTL1TSHRHTT
SCHEMBL22358183 0.82 HTT (0.56) MEN1KMT2AL3MBTL1TSHRHTT
SCHEMBL20116550 0.81 SMO (0.53) MEN1KMT2AL3MBTL1TSHRHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117777121-A Compounds and uses thereof 詹森药业有限公司 2024-03-29 — — CN disclosed
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 — — US disclosed
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 — — US disclosed
CN-110099898-B Compounds and uses thereof 优曼尼蒂治疗公司 2023-07-25 — — CN disclosed
EP-3700934-A1 COMPOUNDS AND USES THEREOF Yumanity Therapeutics, Inc. (US) 2020-09-02 — — EP disclosed
US-20200262828-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2020-08-20 — — US disclosed
WO-2019209948-A9 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS, INC. (US) 2020-01-02 — — WO disclosed
WO-2019209948-A9 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS, INC. (US) 2020-01-02 — — WO disclosed
WO-2019018795-A1 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS (US) 2019-01-24 — — WO disclosed
WO-2019018795-A1 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS (US) 2019-01-24 — — WO disclosed
WO-2018081167-A1 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS (US) 2018-05-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11873298-B2 Compounds and uses thereof NLN, ACHE, CLN6 MEN1 1807/4885KMT2A 2479/4885L3MBTL1 3366/4885
US-20200262828-A1 COMPOUNDS AND USES THEREOF NLN, ACHE, CLN6 MEN1 1807/4885KMT2A 2479/4885L3MBTL1 3366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.